BRPI0411598A - espirobenzazepinas substituìdas - Google Patents

espirobenzazepinas substituìdas

Info

Publication number
BRPI0411598A
BRPI0411598A BRPI0411598-8A BRPI0411598A BRPI0411598A BR PI0411598 A BRPI0411598 A BR PI0411598A BR PI0411598 A BRPI0411598 A BR PI0411598A BR PI0411598 A BRPI0411598 A BR PI0411598A
Authority
BR
Brazil
Prior art keywords
heart failure
hypertension
formula
substituted
treating conditions
Prior art date
Application number
BRPI0411598-8A
Other languages
English (en)
Inventor
Mona Patel
Philip J Rybczynski
Min Amy Xiang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0411598A publication Critical patent/BRPI0411598A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"ESPIROBENZAZEPINAS SUBSTITUìDAS". A presente invenção refere-se a benzazepinas substituídas não - peptídicas de fórmula (I), que são úteis como antagonistas do receptor de vasopressina para tratar condições associadas a atividade do receptor de vasopressina, tais como aquelas que envolvem resistência vascular aumentada e insuficiência cardíaca, incluindo insuficiência cardíaca congestiva, hiponatremia e hipertensão, entre outras descritas. Também estão descritas composições farmacêuticas compreendendo um composto de fórmula (I) e métodos para tratar condições, tais como hipertensão, insuficiência cardíaca congestiva, insuficiência cardíaca, vasoespasmo coronário, isquemia cardíaca, cirrose hepática, vasoespasmo renal, insuficiência renal, nefropatia diabética, edema cerebral, isquemia cerebral, derrame, trombose ou retenção de líquido.
BRPI0411598-8A 2003-06-17 2004-06-16 espirobenzazepinas substituìdas BRPI0411598A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47937803P 2003-06-17 2003-06-17
PCT/US2004/019460 WO2005037795A2 (en) 2003-06-17 2004-06-16 Substituted spirobenzazepines

Publications (1)

Publication Number Publication Date
BRPI0411598A true BRPI0411598A (pt) 2006-08-29

Family

ID=34465052

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411598-8A BRPI0411598A (pt) 2003-06-17 2004-06-16 espirobenzazepinas substituìdas

Country Status (30)

Country Link
US (2) US20040266752A1 (pt)
EP (1) EP1633719B1 (pt)
JP (1) JP5252614B2 (pt)
KR (1) KR101086246B1 (pt)
CN (1) CN100467454C (pt)
AR (1) AR044782A1 (pt)
AT (1) ATE444953T1 (pt)
AU (1) AU2004281257C1 (pt)
BR (1) BRPI0411598A (pt)
CA (1) CA2529649C (pt)
CL (1) CL2004001507A1 (pt)
CR (1) CR8168A (pt)
CY (1) CY1109585T1 (pt)
DE (1) DE602004023501D1 (pt)
DK (1) DK1633719T3 (pt)
EA (1) EA011089B1 (pt)
ES (1) ES2332724T3 (pt)
HR (2) HRP20051006A2 (pt)
IL (1) IL172630A (pt)
ME (1) ME00320B (pt)
NO (1) NO20060247L (pt)
NZ (1) NZ544180A (pt)
PL (1) PL1633719T3 (pt)
PT (1) PT1633719E (pt)
RS (1) RS20050930A (pt)
SI (1) SI1633719T1 (pt)
TW (1) TWI354555B (pt)
UA (1) UA82236C2 (pt)
WO (1) WO2005037795A2 (pt)
ZA (1) ZA200600430B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007516177A (ja) * 2003-06-17 2007-06-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非ペプチド置換スピロベンゾアゼピン誘導体の製造方法
CA2637838A1 (en) * 2006-01-20 2007-07-26 Janssen Pharmaceutica N.V. Novel solid forms of (4r)-1-¬4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl|-1,2,3,5-tetrahydro-spiro¬4h-1-benzazepine-4,1'-¬2|cyclopentene|-3'-carboxylic acid
CN101541806A (zh) 2006-09-22 2009-09-23 詹森药业有限公司 用作血管升压素拮抗剂的螺环苯并氮杂
JP2010504352A (ja) * 2006-09-22 2010-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ バソプレッシン拮抗薬としてのスピロベンズアゼピン類
AR066834A1 (es) * 2007-06-06 2009-09-16 Janssen Pharmaceutica Nv Espirobenzoazepanos como antagonistas de vasopresina, composiciones farmaceuticas que los contienen, proceso de preparacion y usos para el tratamiento de afecciones cardiacas, renales y del sistema nervioso central.
JP2011503085A (ja) * 2007-11-07 2011-01-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アンギオテンシン変換酵素阻害剤及びバソプレッシン受容体拮抗薬を含む複合治療
US20150238502A1 (en) 2012-10-18 2015-08-27 University Of South Florida Compositions and Methods for Treating Stroke
RU2642783C2 (ru) 2012-12-26 2018-01-26 Санва Кагаку Кенкюсо Ко., Лтд. Новое производное бензоазепина и его медицинское применение

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617302A (en) 1984-10-15 1986-10-14 Eli Lilly And Company Inotropic agents
US5985869A (en) * 1989-10-20 1999-11-16 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
ES2089033T3 (es) 1989-10-20 1996-10-01 Otsuka Pharma Co Ltd Compuestos benzoheterociclicos.
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5849780A (en) 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
CA2143117A1 (en) * 1992-10-07 1994-04-14 Ben E. Evans Tocolytic oxytocin receptor antagonists
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
PT758895E (pt) * 1994-04-22 2000-05-31 Univ Kingston Formas de dosagem sublingual contendo apomorfina para uso no tratamento da disfuncao erectil
US5753648A (en) 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
JP3282494B2 (ja) * 1995-05-16 2002-05-13 富士ゼロックス株式会社 画像定着装置
US5753715A (en) 1995-06-02 1998-05-19 Ortho Pharmaceutical Corporation 2-disubstituted cyclohexenyl and cyclohexyl antimicrobial agents
US5726723A (en) * 1996-01-31 1998-03-10 Technology Research International Corporation Sub-twisted nematic liquid crystal display
AUPP150098A0 (en) 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
ATE305454T1 (de) * 2000-07-05 2005-10-15 Ortho Mcneil Pharm Inc Nichtpeptidische substituierte spirobenzoazepine als vasopressin antagonisten
JP2007516177A (ja) 2003-06-17 2007-06-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非ペプチド置換スピロベンゾアゼピン誘導体の製造方法

Also Published As

Publication number Publication date
AU2004281257B2 (en) 2010-02-04
EP1633719A2 (en) 2006-03-15
TW200515911A (en) 2005-05-16
HRP20090606T1 (hr) 2010-01-31
JP5252614B2 (ja) 2013-07-31
PL1633719T3 (pl) 2010-03-31
EA200501831A1 (ru) 2006-06-30
WO2005037795A2 (en) 2005-04-28
RS20050930A (en) 2008-04-04
US20040266752A1 (en) 2004-12-30
CR8168A (es) 2008-09-10
CA2529649A1 (en) 2005-04-28
ES2332724T3 (es) 2010-02-11
AR044782A1 (es) 2005-10-05
AU2004281257A1 (en) 2005-04-28
ZA200600430B (en) 2009-08-26
CY1109585T1 (el) 2014-08-13
IL172630A0 (en) 2006-04-10
CN1835925A (zh) 2006-09-20
EA011089B1 (ru) 2008-12-30
DE602004023501D1 (de) 2009-11-19
ATE444953T1 (de) 2009-10-15
TWI354555B (en) 2011-12-21
JP2007521272A (ja) 2007-08-02
PT1633719E (pt) 2009-11-11
US7687494B2 (en) 2010-03-30
KR101086246B1 (ko) 2011-11-23
US20070179128A1 (en) 2007-08-02
NZ544180A (en) 2009-01-31
CN100467454C (zh) 2009-03-11
MEP49108A (en) 2011-02-10
CL2004001507A1 (es) 2005-05-27
DK1633719T3 (da) 2010-01-04
UA82236C2 (en) 2008-03-25
IL172630A (en) 2011-10-31
EP1633719B1 (en) 2009-10-07
KR20060023157A (ko) 2006-03-13
WO2005037795A3 (en) 2005-07-28
SI1633719T1 (sl) 2010-01-29
ME00320B (me) 2011-05-10
CA2529649C (en) 2012-01-31
AU2004281257C1 (en) 2010-07-01
NO20060247L (no) 2006-03-13
HRP20051006A2 (en) 2006-05-31

Similar Documents

Publication Publication Date Title
BRPI9917086B8 (pt) benzodiazepina tricíclica, suas composições farmacêuticas bem como compostos intermediários
PL2078022T3 (pl) Spirobenzoazepiny stosowane jako antagoniści wazopresyny
ATE384050T1 (de) Benzazepinderivate als histamin-h3-antagonisten
CR8168A (es) Espirobenzazepinas sustituidas
BR0112372A (pt) Espirobenzoazepinas substituìdas por não-peptìdeo como antagonistas de vasopressina
DE602004011204D1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
BRPI0412843A (pt) lactamas substituìdas e uso das mesmas como agentes anticáncer
MY144635A (en) 2-oxo-1,2,4,5-tetrahydro-1,-3-benzodiazepin-3-yl-piperidines used as cgrp antagonists
BR0015299A (pt) Benzotiazepinas substituìdas não-peptìdicas como antagonistas de vasopressina
DK1214323T3 (da) Indoloazepiner som vasopressinreceptorantagonister
PE20001416A1 (es) Uso de difenil-acetanilidas como antagonistas de neuropeptidos y
WO2006049984A3 (en) Novel [1,4]benzodiazepines as vasopressin v2 receptor antagonists
TH87268B (th) ไธอิโนไพราโซล
TH87268A (th) ไธอิโนไพราโซล

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 10, 13 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]